Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation
Clinical and Translational Medicine · 2026
DOI: 10.1002/ctm2.70676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Yifan Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Pe…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Karyopherins, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Background
Exportin‐1 (XPO1), a key regulator of nucleocytoplasmic transport, is frequently dysregulated in acute myeloid leukemia (AML) and contributes to leukemogenesis, disease progression and therapeutic resistance. Selective inhibitors of nuclear export (SINEs), especially selinexor and eltanexor, have shown promising antileukemic potential. However, their clinical value, optimal therapeutic positioning and rational use in AML remain to be fully clarified.
Methods
We collected and reviewed relevant literature to summarize the biological roles of XPO1 in AML and the therapeutic potential of XPO1 inhibitors in preclinical and clinical settings.
Results
In this review, we focus on the nuclear export function of XPO1 and its pathogenic role in AML. We summarize the mechanisms of action, preclinical evidence, clinical trial results, adverse effects, resistance mechanisms and potential response biomarkers associated with XPO1 inhibitors in AML.
Conclusions
XPO1 inhibition has emerged as a promising therapeutic strategy for AML, offering a novel approach to targeting aberrant nucleocytoplasmic transport and overcoming treatment resistance. Future studies should focus on optimizing dosing schedules, identifying predictive biomarkers and developing effective combination strategies in molecularly selected AML populations. Key Points XPO1 hyperactivation rewires nucleocytoplasmic transport and sustains leukaemogenic programs in genetically defined acute myeloid leukaemia (AML) subsets. Selective XPO1 inhibitors (selinexor, eltanexor) show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms. Combination strategies with hypomethylating agents, BCL‐2 inhibitors and other targeted therapies enhance depth and durability of responses but are limited by toxicity. Future clinical trials should focus on molecularly selected populations, biomarker‐guided dosing and translational endpoints such as measurable residual disease (MRD) and clonal dynamics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Clinical Laboratories,…
Förderung
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Liu, Y., Yun, X., Ding, W., Li, S., & Liu, H. (2026). Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70676
Vancouver
Liu Y, Yun X, Ding W, Li S, Liu H. Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70676
BibTeX
@article{Liu2026,
author = {Liu, Yifan and Yun, Xiaoya and Ding, Weidong and Li, Suxiao and Liu, Hui},
title = {Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation},
journal = {Clinical and Translational Medicine},
year = {2026},
doi = {10.1002/ctm2.70676}
}
EUVIMED